April 26, 2021 – Quidel Corporation (San Diego, CA) announced it has completed a distribution and fulfillment agreement with McKesson Corporation, a global leader in healthcare supply chain management solutions and retail pharmacy, to expedite consumer access to Quidel’s non-prescription QuickVue At-Home OTC COVID-19 Test.
The agreement with McKesson will enable Quidel to continue to supply existing customers in the professional segment and also reach significant new markets as the company introduces its new over-the-counter COVID-19 antigen product for retail markets and testing for reopening schools, and for health departments, employers, entertainment centers, and many other locations.
McKesson will be Quidel’s lead commercial partner in fulfilling QuickVue At-Home OTC COVID-19 rapid antigen test orders to individuals and businesses with the following support:
- Access to multiple retailers, where McKesson will accelerate Quidel’s product roll-out strategy.
- Availability to McKesson’s Health Mart franchise, allowing Quidel access to a network of over 5,000 independent pharmacies.
- E-commerce support; ability to rapidly introduce products across multiple e-commerce sites, such as Amazon, eBay, and Simply Medical, McKesson’s home health e-commerce site.
The QuickVue At-Home OTC COVID-19 Test received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in March. The QuickVue At-Home OTC COVID-19 Test allows consumers to easily perform the test themselves without a doctor’s prescription and get highly accurate results in 10 minutes or less from nasal swab samples, the company says.
Quidel says that it expects shipping of the QuickVue At-Home OTC COVID-19 Test to begin early next week and be available from McKesson and its customer outlets soon thereafter.